Looking for a new broker?
Black Diamond Therapeutics, Inc. stock is up 18.95% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 3 December’s closed higher than November. 100% of analysts rate it a buy.
Black Diamond Therapeutics, Inc. discovers, develops, and commercializes medicines for patients with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by non-canonical epidermal growth factor receptor (EGFR) mutations. The company is also developing a brain-penetrant inhibitor of EGFR mutations.
